Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Findit who wrote (100196)	12/4/2003 9:11:41 AM
From: wlcnyc	Read Replies (1) \| Respond to of 208838

CRDM - That's exactly what I was about to say - "without me"! Bill

To: Findit who wrote (100196)	12/4/2003 9:11:51 AM
From: Findit	Read Replies (1) \| Respond to of 208838

Thursday December 4, 9:06 am ET FREMONT, Calif.--(BUSINESS WIRE)--Dec. 4, 2003--Cardima®, Inc. (NasdaqSC:CRDM) has signed a distribution agreement with Dr. Osypka GMBH Medizinintechnik for the distribution of Cardima's CE marked products in Germany. The terms of the agreement were not disclosed. "This agreement completes our transition to selling through distribution channels in our four targeted regions within Europe," said Gabriel Vegh, Chairman and CEO of Cardima. "We are excited about initiating a relationship with Dr. Osypka GMBH, a leader with strong electrophysiology presence in a very important market. The founder, Dr. Osypka, is one of the pioneers of RF ablation and noted as an innovator and value conscious creator of many of the tools being used today in electrophysiology. He and his company are held in high regard and we look forward to expanding our revenue capability with our full line of electrophysiology products in Germany." The agreement was effective December 1, 2003. This completed agreement follows Cardima's recent receipt of a CE Mark approval to introduce its new REVELATION Helix STX in Europe. This technology enhancement builds on the work done previously with the REVELATION Helix models introduced in Europe in 2002. Dr. Osypka GMBH Medizinintechnik's headquarters' is located in Rheinfelden-Herten, Germany. The company is family owned with more than 180 employees and specializes in the development, manufacturing and distribution of implantable and temporary pacing leads catheters and generators for cardiac mapping and radio-frequency (RF) ablation. About Cardima Cardima, Inc. has developed the REVELATION® Tx, REVELATION T-Flex and REVELATION Helix linear ablation microcatheter systems for the minimally invasive treatment of atrial fibrillation (AF). The REVELATION Helix was developed for the treatment of AF originating in the pulmonary veins of the heart. The REVELATION Tx, REVELATION T-Flex and REVELATION Helix systems have received CE Mark approval in Europe. The Company has also developed a Surgical Ablation System, which is expected to be used by cardiac surgeons to treat AF by ablating cardiac tissue during heart surgery using radio frequency (RF) energy. In February 2003, the Company announced that it had received FDA 510(k) clearance to market the Surgical Ablation System in the U.S. Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to raise additional capital, whether the Company's pre-market approval application for the REVELATION® Tx or any other product will be approved by the FDA, whether the Company will be able to conduct successful clinical trials, obtain regulatory approvals, gain acceptance for its products from the marketplace and whether the Company will be able to successfully market, sell and derive significant revenue from its products, including REVELATION® Tx. Additional risks are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission on March 31, 2003. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. -------------------------------------------------------------------------------- Contact: Cardima, Inc. Barry D. Michaels, 510-354-0300 www.cardima.com or Investors: Investor Relations Group Shayne Payne, John Nesbett or Dian Griesel, Ph.D. 212-825-3210 or Media: Investor Relations Group Janet Vasquez or Dian Griesel, Ph.D. 212-825-3210